Bayer Aktiengesellschaft

Siemens Healthcare Diagnostics Gmbh

Bayer Technology Services Gmbh

Biontech Diagnostics Gmbh

Sividon Diagnostics Gmbh

Wirtz, Ralph

Udo Stropp

Axel Kretschmer

Burkhard Mielke

Horst-Peter Antonicek

Arnd Voerste

Jean-Marie-Viktor De Vry

Andreas Stolle

Rudy Schreiber

Karsten Von Dem Bruch

J&ouml;rg Baumgarten

Ervin Horv&aacute;th

Gerhard M&uuml;ller

Stephen Lensky

Thomas M&uuml;ller

Eckhard Schwenner

Wolfgang Springer

Christoph Schwemler

Antonius Lobberding

Helga Rubsamen-Waigmann

Thorsten Potter

Lothar Biesert

Jorg Baumgarten

Ralf Kronenwett

Winfried Kosch

Hansjorg Durr

Rolf Burghaus

Andreas Schuppert

Antonius L Obberding

Harald Kallabis

Thorsten P Otter

Antonius Loebberding

Mark-Michael Struck

Hary Suhartono

Thomas-Peter Hausner

Karsten Weber

Haryadi Suhartono

Axel C Heitmann

Chrisian Von Töerne

Stephan Schwers

Mathias Gehrmann

Christian Von Toerne

George Fountzilas

Ralph Wirtz

Marc Munnes

Methods for increasing multiplex level by externalization of a passive reference in polymerase chain reactions (PCR) are provided. An exemplary method comprises providing a first mastermix including a passive fluorescence dye in at least a first well of a plate; providing a second mastermix including an active fluorescence dye in at least a second well of the plate; wherein the passive fluorescence dye and the active fluorescence dye emit a same spectrum and an intensity of the spectrum is adapted to be measured; and wherein the first mastermix is devoid of an active fluorescence dye emitting the same spectrum and the second mastermix is devoid of the passive fluorescence dye emitting the same spectrum. Numerous other aspects are provided.

Increasing multiplex level by externalization of passive reference in polymerase chain reactions

The invention relates to a method for developing a biomarker for the prognosis of the result of a therapeutical treatment based on data obtained in clinical studies, data remaining unchanged by therapy being subdivided into diagnostic and genomic parameters and the marker being defined by a combination of parameters. The method according to the invention is characterized by specifying the maximum number of parameters for defining the marker and thus the maximum complexity of the system from the beginning and by carrying out the search for defining parameters by sequential combination of clinical parameters (=z parameters) and/or genomic parameters (=x parameters).

Method for identifying predictive biomarkers from patient data

The present invention relates to novel substituted &agr;,&bgr;-fused butyrolactones, to processes for their preparation and to their use for the prevention and/or treatment of disorders caused by hyper- or hypofunction of the glutamatergic system, in particular of cerebral ischaemias, craniocerebral trauma, states of pain or CNS-mediated spasms.

Substituted &agr;, &bgr;-anellated butyrolactones

The present invention relates to novel substituted (&agr;,&bgr;-fused butyrolactones, to processes for their preparation and to their use for the prevention and/or treatment of disorders caused by hyper- or hypofunction of the glutamatergic system, in particular of cerebral ischaemias, craniocerebral trauma, states of pain or CNS-mediated spasms.

The present invention relates to novel substituted &bgr;,&ggr;-fused lactones, to processes for their preparation and to their use for the prevention and/or treatment of disorders caused by hyper- or hypofunction of the glutamatergic system, in particular of cerebral ischaemias, craniocerebral trauma, states of pain or CNS-mediated spasms.

Substituted &bgr;,&ggr;-anellated lactones

The present invention relates to novel substituted bicyclic lactones, to processes for their preparation and to their use for the prevention and/or treatment of disorders caused by hyper- or hypofunction of the glutamatergic system, in particular of cerebral ischaemias, cranial cerebral trauma, states of pain or CNS-mediated spasms.

Substituted bicyclic lactones

The present invention relates to compounds of the general formula (I), ##STR1## in which the radicals have the meaning given in the description, to processes for their preparation and to their use as medicaments.

Nucleic acid-binding oligomers for therapy and diagnosis

The invention relates to nucleic acid-binding oligomers possessing C-branching of the general formula (I) ##STR1## and to the corresponding monomers, whose radicals have the meaning given in the description, and to their use as medicaments or diagnostic aids.

Nucleic acid-binding oligomers possessing C-branching for therapy and

The invention relates to nucleic acid-binding oligomers possessing N-branching of the general formula (I), ##STR1## and their monomers, where the individual radicals have the meaning given in the description, and to their use as medicaments or as aids in diagnostics.

Nucleic acid-binding oligomers possessing N-branching for therapy and

The present invention relates to the targeted blocking of the genetic information of the viral messenger ribonucleic acid (mRNA) for virus replication (e.g. of HIV) in transfected, haematopoietic cells with particularly suitable expression systems, which express a complementary 'antisense RNA'.

HIV antisense expression vectors

Novel oligophosphates with an antiviral action of the formula ##STR1## in which n is 3-50,

Oligophosphates with an antiviral action

Growing community of inventors

Haan, Germany

Udo Stropp